Multiple studies have shown that ACLY is highly expressed in tumors, including gastric cancer 29, non-cellular lung cancer 30, breast cancer (BC) 31, and ovarian cancer 32, and is associated with poor prognosis. Here, ACLY is linked to breast cancer.